John Paulus, DO
Internal Medicine · Cheyenne, WYNPI 1841200797
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Novo Nordisk at 32.0% of the total. Reporting peaked in 2022 at $111 and has fallen 85.9% since, to $16 in 2025.
Across 9 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$53
- Ultragenyx Pharmaceutical Inc.$23
- Fidia Pharma USA Inc.$22
- Bioventus LLC$19
- Idorsia Pharmaceuticals US Inc$18
- Lilly USA, LLC$16
- plus $16 from 1 others
What the payments were for
- Food & beverage$166100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 3 | $53 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Fidia Pharma USA Inc. | 1 | $22 |
| Bioventus LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
How this compares
$166 in reported general payments places this provider in the 70th percentile of 101 internal medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $20,261 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $7,919 |
| PremarinEstrogens, Conjugated | 14 | $7,489 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $3,550 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,614 |
| Gabapentin | 57 | $1,486 |
| Np ThyroidThyroid,pork | 14 | $1,041 |
| Probenecid-ColchicineProbenecid/Colchicine | 16 | $957 |
| Metoprolol Succinate | 48 | $749 |
| Hydroxychloroquine Sulfate | 15 | $636 |
| SynthroidLevothyroxine Sodium | 16 | $623 |
| Lisinopril | 62 | $562 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $483 |
| Levothyroxine Sodium | 69 | $465 |
| Amlodipine Besylate | 53 | $402 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Cheyenne
- Daniel RivardCheyenne$193
- Raja Shekar Rao JadavCheyenne$137
- Anusha KondapalliCheyenne$102
- Paul WashburnCheyenne$96
- William HarrisonCheyenne$47
- Israel StewartRock Springs$6K
- Michelle NeiceDouglas$4K
- David WalkerSheridan$3K
- Juli AckermanSheridan$3K
- Hannah HallSheridan$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.